Abstract
Objective: To evaluate remission and relapse rates in patients with Graves’ disease treated with methimazole and to identify clinical and laboratory predictors of these outcomes. Subjects and methods: We conducted a retrospective cohort study of 425 adult patients newly diagnosed with Graves’ disease at a single tertiary center between 2002 and 2022. All patients received methimazole for at least 12 months. Remission was defined as drug-free biochemical euthyroidism for 12 months or longer after therapy withdrawal. Univariate and multivariate [...] ABSTRACT Objective: To evaluate remission and relapse rates in patients with Graves’ disease treated with methimazole and to identify clinical and laboratory predictors of these outcomes. Subjects and methods: We conducted a retrospective cohort study of 425 adult patients newly diagnosed with Graves’ disease at a single tertiary center between 2002 and 2022. All patients received methimazole for at least 12 months. Remission was defined as drug-free biochemical euthyroidism for 12 months or longer after therapy withdrawal. Univariate and multivariate